DE69434697D1 - Therapeutische Verwendungen von Dehydroepiandrosteron zur Behandlung von verminderter Libido und Osteoporose - Google Patents

Therapeutische Verwendungen von Dehydroepiandrosteron zur Behandlung von verminderter Libido und Osteoporose

Info

Publication number
DE69434697D1
DE69434697D1 DE69434697T DE69434697T DE69434697D1 DE 69434697 D1 DE69434697 D1 DE 69434697D1 DE 69434697 T DE69434697 T DE 69434697T DE 69434697 T DE69434697 T DE 69434697T DE 69434697 D1 DE69434697 D1 DE 69434697D1
Authority
DE
Germany
Prior art keywords
treatment
dehydroepiandrosterone
precursors
osteoporosis
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69434697T
Other languages
English (en)
Other versions
DE69434697T2 (de
Inventor
Fernand Labrie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ENDORECH Inc
Endorecherche Inc
Original Assignee
ENDORECH Inc
Endorecherche Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/180,361 external-priority patent/US5776923A/en
Application filed by ENDORECH Inc, Endorecherche Inc filed Critical ENDORECH Inc
Publication of DE69434697D1 publication Critical patent/DE69434697D1/de
Application granted granted Critical
Publication of DE69434697T2 publication Critical patent/DE69434697T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/006—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
DE69434697T 1993-01-19 1994-01-19 Therapeutische Verwendungen von Dehydroepiandrosteron zur Behandlung von verminderter Libido und Osteoporose Expired - Lifetime DE69434697T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US561993A 1993-01-19 1993-01-19
US5619 1993-01-19
US180361 1994-01-18
US08/180,361 US5776923A (en) 1993-01-19 1994-01-18 Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone

Publications (2)

Publication Number Publication Date
DE69434697D1 true DE69434697D1 (de) 2006-05-18
DE69434697T2 DE69434697T2 (de) 2007-03-29

Family

ID=26674550

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69433994T Expired - Lifetime DE69433994T2 (de) 1993-01-19 1994-01-19 Therapeutische verwendungen und verabreichungsysteme von dehydroepiandrosteron
DE69434697T Expired - Lifetime DE69434697T2 (de) 1993-01-19 1994-01-19 Therapeutische Verwendungen von Dehydroepiandrosteron zur Behandlung von verminderter Libido und Osteoporose

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69433994T Expired - Lifetime DE69433994T2 (de) 1993-01-19 1994-01-19 Therapeutische verwendungen und verabreichungsysteme von dehydroepiandrosteron

Country Status (18)

Country Link
US (7) US5948434A (de)
EP (1) EP0680327B1 (de)
JP (1) JP3441730B2 (de)
CN (2) CN1439375B (de)
AT (2) ATE322271T1 (de)
AU (2) AU686120B2 (de)
CZ (1) CZ297860B6 (de)
DE (2) DE69433994T2 (de)
DK (1) DK0680327T3 (de)
ES (2) ES2261836T3 (de)
FI (1) FI953017A (de)
HU (1) HU228385B1 (de)
IL (1) IL108371A (de)
NO (6) NO952417L (de)
NZ (2) NZ512334A (de)
PT (2) PT680327E (de)
SK (1) SK286051B6 (de)
WO (1) WO1994016709A2 (de)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5407927A (en) * 1993-04-16 1995-04-18 The Regents Of The University Of California Treatment of mild depression and restoration of IGF-I levels in aging by dehydroepiandrosterone
FR2729854A1 (fr) * 1995-01-26 1996-08-02 Oreal Utilisation du sulfate de dehydroepi-androsterone dans une composition cosmetique ou dermatologique
US20020032160A1 (en) * 1995-02-24 2002-03-14 Nyce Jonathan W. Compositions & formulations with an epiandrosterone or a ubiquinone & kits & their use for treatment of asthma symptoms & for reducing adenosine/adenosine receptor levels
US5660835A (en) * 1995-02-24 1997-08-26 East Carolina University Method of treating adenosine depletion
ES2098193B1 (es) * 1995-07-21 1997-12-01 Gomez Jesus Calderon Nueva formulacion farmaceutica de dehidroepiandrosterona para aplicacion topica percutanea.
DE19619045C1 (de) * 1996-05-02 1997-11-13 Jenapharm Gmbh Verwendung von Kombinationspräparaten zur Behandlung hypogonadaler Männer sowie Männern mit Hypophysenerkrankungen
US6228852B1 (en) * 1996-07-12 2001-05-08 Carolyn V. Shaak Transdermal application of naturally occurring steroid hormones
US6514937B1 (en) 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
US6025368A (en) * 1997-02-25 2000-02-15 Celtrix Pharmaceuticals, Inc. Method for treating the symptoms of chronic stress-related disorders using IGF
US6015786A (en) * 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
US7169768B1 (en) * 1997-03-18 2007-01-30 Weisman Kenneth M Method of decreasing atherosclerosis and its complications
US5912240A (en) 1997-04-10 1999-06-15 Loria; Roger M. 5-androstene 3β, 17α diol as an inhibitor of tumor growth
IT1291141B1 (it) * 1997-04-16 1998-12-29 Sigma Tau Ind Farmaceuti Composizione farmaceutica comprendente una alcanoil l-carnitina, atta a stimolare la moltiplicazione e la crescita degli osteoblasti
US6140315A (en) * 1997-06-09 2000-10-31 Weisman; Kenneth M. Therapeutic uses of goserelin acetate
US6117429A (en) * 1997-08-11 2000-09-12 Weider Nutrition International, Inc Compositions and treatments for reducing potential unwanted side effects associated with long-term administration of androgenic testosterone precursors
US5968919A (en) * 1997-10-16 1999-10-19 Macrochem Corporation Hormone replacement therapy drug formulations for topical application to the skin
US6093389A (en) * 1997-12-01 2000-07-25 American Cyanamid Company Methods and compositions for attracting and controlling termites
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
KR20060098400A (ko) * 1998-06-11 2006-09-18 앙도르쉐르슈 인코포레이티드 안드로스트-5-엔-3β,17β-디올을 포함하는 약학 조성물 및그 용도
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
FR2789312B1 (fr) * 1999-02-05 2003-10-17 Seporga Sterol 3 sulfates, nouveaux principes actifs a usage cosmetique et dermatologique, et leurs applications
US7045513B1 (en) * 1999-03-18 2006-05-16 Genelabs Technologies, Inc. DHEA composition and method
AU777770C (en) 1999-05-04 2005-11-10 Strakan International Limited Androgen glycosides and androgenic activity thereof
AU2004222794B2 (en) * 1999-06-11 2007-03-08 Watson Pharmaceuticals, Inc. Non-oral androgenic steroids for women
MXPA01012769A (es) * 1999-06-11 2003-06-24 Watson Pharmaceuticals Inc Administracion de esteroides androgenicos no orales para mujeres.
DK1955700T3 (da) 1999-09-30 2011-05-23 Harbor Biosciences Inc Terapeutisk behandling af androgenreceptor-betingede lidelser
WO2001026651A2 (en) * 1999-10-14 2001-04-19 Endorecherche, Inc. Selective estrogen receptor modulators in the treatment or reduction of the risk of acquiring hypertension, cardiovascular diseases, and insulin resistance
FR2803750B1 (fr) * 2000-01-17 2004-04-02 Assist Publ Hopitaux De Paris Utilisation par voie orale de la dehydroepiandrosterone, de ses precurseurs biologiques et de ses derives metaboliques comme anti-atrophiant
AU2001241779A1 (en) 2000-02-25 2001-09-03 Hollis-Eden Pharmaceuticals, Inc. Method of treatment of prostate cancer
FR2807323A1 (fr) 2000-04-10 2001-10-12 Oreal Composition, notamment cosmetique, renfermant un steroide et un 2-alkyl alcanol ou un ester
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
BR0113649A (pt) * 2000-08-30 2004-07-20 Unimed Pharmaceuticals Inc Processo para aumentar a testosterona e as relacionadas concentrações de esteróide em mulheres
US20020072509A1 (en) * 2000-10-11 2002-06-13 Stein Donald Gerald Methods for the treatment of a traumatic central nervous system injury
AU2002303427A1 (en) * 2001-04-24 2002-11-05 East Carolina University Compositions and formulations with a non-glucocorticoid steroid and/or a ubiquinone and kit for treatment of respiratory and lung disease
AU2002303425A1 (en) * 2001-04-24 2002-11-05 Epigenesis Pharmaceuticals, Inc. Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent
FR2826011B1 (fr) * 2001-06-14 2004-12-10 Oreal Nouveaux derives de la 7-oxo-dhea et utilisation cosmetique
EP1406633B1 (de) 2001-06-18 2011-10-05 Noven Pharmaceuticals, Inc. Verbesserte arzneimittelabgabe in transdermalen systemen
EP1285927A3 (de) * 2001-08-16 2005-06-29 Schering Aktiengesellschaft Verwendung von Glucocorticoid-Rezeptorantagonisten zur Vorbeugung und Behandlung von Erkrankungen des männlichen Reproduktionssystems
US6805878B2 (en) 2001-09-13 2004-10-19 Noven Pharmaceuticals, Inc. Transdermal administration of ACE inhibitors
FR2831441B1 (fr) * 2001-10-25 2003-12-26 Oreal Utilisation cosmetique de derives de la dhea
ATE356635T1 (de) * 2001-11-15 2007-04-15 Pantarhei Bioscience Bv Verfahren zur vorbeugung oder behandlung von benignen gynäkologischen störungen
AU2003206442A1 (en) * 2002-02-21 2003-09-09 Pantarhei Bioscience B.V. Estrogenic component for treating decreased libido in women
WO2003084547A1 (en) * 2002-04-03 2003-10-16 Barr Laboratories, Inc. Step-down estrogen therapy
AU2003224561A1 (en) * 2002-04-23 2003-11-10 Sahltech I Goteborg Ab Use of dhea for treatment of female hypopituitarism
US7405207B2 (en) * 2002-06-17 2008-07-29 Epigenesis Pharmaceuticals, Inc. Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof
JP2005537296A (ja) * 2002-06-17 2005-12-08 エピジェネシス ファーマシューティカルズ リミティド ライアビリティー カンパニー デヒドロエピアンドロステロンの噴霧器製剤及びその組成物を使用することでの喘息又は慢性閉塞性肺疾患を治療するための方法
WO2004091535A2 (en) * 2003-04-11 2004-10-28 Barr Laboratories, Inc. Methods of administering estrogens and progestins
US20050026884A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050026890A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an antihistamine for treatment of asthma or chronic obstructive pulmonary disease
US20090263381A1 (en) * 2003-07-31 2009-10-22 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease
US20050026882A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20050026881A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-IgE antibody for treatment of asthma or chronic obstructive pulmonary disease
US20110209699A1 (en) * 2003-07-31 2011-09-01 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050101545A1 (en) * 2003-07-31 2005-05-12 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20090285899A1 (en) * 2003-07-31 2009-11-19 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a methylxanthine derivative for treatment of asthma or chronic obstructive pulmonary disease
US20050043282A1 (en) * 2003-07-31 2005-02-24 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20090297611A1 (en) * 2003-07-31 2009-12-03 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or vcam inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050038004A1 (en) * 2003-07-31 2005-02-17 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050026879A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or VCAM inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050026848A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a methylxanthine derivative for treatment of asthma or chronic obstructive pulmonary disease
US20050085430A1 (en) * 2003-07-31 2005-04-21 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050026880A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a cromone for treatment of asthma or chronic obstructive pulmonary disease
US20050026883A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20090285900A1 (en) * 2003-07-31 2009-11-19 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050113318A1 (en) * 2003-07-31 2005-05-26 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20090274676A1 (en) * 2003-07-31 2009-11-05 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a pde-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US8147472B2 (en) 2003-11-24 2012-04-03 Kimberly-Clark Worldwide, Inc. Folded absorbent product
US20050181057A1 (en) * 2004-02-13 2005-08-18 Rosenberg Paul K. Vaginal lubricant
RS20070166A (en) 2004-10-20 2008-09-29 Endorecherche Inc., Sex steroid precursors alone or in combination with a selective estrogen receptor modulator...
EA200700983A1 (ru) * 2004-11-01 2008-04-28 Эндорешерш, Инк. Применение андрогенов для снижения вероятности приобретения или лечения старения кожи
PL1868614T3 (pl) * 2005-03-24 2013-01-31 Univ Emory Schemat dawkowania do leczenia urazowego uszkodzenia mózgu progesteronem
US7473687B2 (en) * 2005-03-24 2009-01-06 Emory University Methods for the treatment of a traumatic central nervous system injury
US8084446B2 (en) 2005-04-26 2011-12-27 Eric Marchewitz Use of DHEA derivatives for enhancing physical performance
TR201815853T4 (tr) 2005-10-12 2018-11-21 Besins Healthcare Sarl Hipogonadizmin tedavisinde kullanıma yönelik geliştirilmiş testosteron jeli.
US20090215731A1 (en) 2005-10-19 2009-08-27 Chavah Pty Ltd. Reduction of Side Effects From Aromatase Inhibitors Used for Treating Breast Cancer
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
US20100317635A1 (en) 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
US9381193B2 (en) * 2011-04-01 2016-07-05 Washington University Contraceptive methods and compositions
BR112014014308A2 (pt) 2011-12-29 2017-06-13 Laboratorios Andrómaco S A anel vaginal que inclui dhea ou sulfato de dhea e, opcionalmente, um agente para modular a liberação do princípio ativo, que pode ser usado para aumentar a reserva ovariana nas mulheres e para aliviar os sintomas associados à menopausa
EP3057667B1 (de) * 2013-10-15 2020-03-04 CHelac Holding GmbH Steroid-carbonsäureester, zusammensetzungen, enthaltend steroid-carbonsäureester und verwendung dieser bei lokal topischer applikation für kosmetische oder dermatologische zwecke
US9744177B2 (en) * 2014-03-10 2017-08-29 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
WO2016061615A1 (en) 2014-10-22 2016-04-28 Chavah Pty Ltd Methods of reducing mammographic breast density and/or breast cancer risk
AU2016343297A1 (en) 2015-10-22 2018-05-10 Havah Therapeutics Pty Ltd Methods of reducing mammographic breast density and/or breast cancer risk
JP7287606B2 (ja) 2018-08-10 2023-06-06 株式会社日本スペリア社 鉛フリーはんだ合金
WO2020243777A1 (en) 2019-06-03 2020-12-10 Havah Therapeutics Pty Ltd Pharmaceutical formulations and systems for delivery of an androgenic agent and an aromatase inhibitor and methods for use
US11690852B2 (en) 2020-12-01 2023-07-04 Endorecherche. Inc. Reduction of the incidence or recurrence of breast cancer in postmenopausal women treated with intravaginal sex steroid precursor

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK122125B (da) * 1967-10-04 1972-01-24 Schering Ag Analogifremgangsmåde til fremstilling af terapeutisk aktive carboxylsyreestere af 3β-hydroxy-5-androstan-17-on(dehydroepiandrosteron) med 7-11 carbonatomer i esterresten.
US3551554A (en) * 1968-08-16 1970-12-29 Crown Zellerbach Corp Enhancing tissue penetration of physiologically active agents with dmso
US3472931A (en) * 1969-01-17 1969-10-14 Foster Milburn Co Percutaneous absorption with lower alkyl amides
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3742951A (en) * 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
JPS505372A (de) * 1973-05-30 1975-01-21
US4006218A (en) * 1974-07-08 1977-02-01 Johnson & Johnson Potentiated medicaments
US3989816A (en) * 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4405616A (en) * 1975-06-19 1983-09-20 Nelson Research & Development Company Penetration enhancers for transdermal drug delivery of systemic agents
US4005200A (en) * 1975-07-17 1977-01-25 Kanebo, Ltd. Method for improving the maturity of the parturient canal and the sensitivity to oxytocin
DE2534911C2 (de) * 1975-08-01 1985-04-18 Schering AG, 1000 Berlin und 4709 Bergkamen Verfahren zur Herstellung von 5-Androsten-17-on-Derivaten
US4213978A (en) * 1978-12-05 1980-07-22 Interx Research Corporation Anti-acne and anti-seborrhea prodrug derivatives of progesterone
US4425339A (en) * 1981-04-09 1984-01-10 Syntex (U.S.A.) Inc. Treatment of menopausal symptoms
FR2518879A1 (fr) * 1981-12-30 1983-07-01 Besins Jean Medicament a base d'oestradiol pour le traitement de la pathologie menopausique
US4397782A (en) * 1982-05-28 1983-08-09 E. R. Squibb & Sons, Inc. Antiinflammatory 17-spiroandrostenes
US4542129A (en) * 1982-08-16 1985-09-17 Norman Orentreich DHEA Formulations and methods for treating dry skin
US4496556A (en) * 1982-08-16 1985-01-29 Norman Orentreich Topical applications for preventing dry skin
SE8303031D0 (sv) * 1983-05-30 1983-05-30 Leo Ab Improved steroid esters preparation
US4518595A (en) * 1983-07-19 1985-05-21 The Jackson Laboratory Method for treating diabetes using DHEA compounds
DE3333240A1 (de) * 1983-09-12 1985-03-28 Schering AG, 1000 Berlin und 4709 Bergkamen Mittel zur transdermalen applikation von arzneimittelwirkstoffen
US4725439A (en) * 1984-06-29 1988-02-16 Alza Corporation Transdermal drug delivery device
US4624665A (en) * 1984-10-01 1986-11-25 Biotek, Inc. Method of transdermal drug delivery
US4568343A (en) * 1984-10-09 1986-02-04 Alza Corporation Skin permeation enhancer compositions
EP0209590A1 (de) * 1985-01-25 1987-01-28 Monell Chemical Senses Center Verwendung männlicher essenz, enthaltende androstenol und dehydroepiandrosteronsulfat bei der behandlung von lutealphasenstörungen und ovulationsabwesenheit bei frauen
US4628052A (en) * 1985-05-28 1986-12-09 Peat Raymond F Pharmaceutical compositions containing dehydroepiandrosterone and other anesthetic steroids in the treatment of arthritis and other joint disabilities
US4680289A (en) * 1985-06-05 1987-07-14 Progenics, Inc. Treatment of obesity and diabetes using sapogenins
US4812447A (en) * 1985-10-22 1989-03-14 City Of Hope Method for the treatment of nervous system degeneration
US4666441A (en) * 1985-12-17 1987-05-19 Ciba-Geigy Corporation Multicompartmentalized transdermal patches
IE60941B1 (en) * 1986-07-10 1994-09-07 Elan Transdermal Ltd Transdermal drug delivery device
JPS63104924A (ja) * 1986-10-20 1988-05-10 Kanebo Ltd 膣坐剤
US4816258A (en) * 1987-02-26 1989-03-28 Alza Corporation Transdermal contraceptive formulations
NL194728C (nl) * 1987-04-16 2003-01-07 Hollis Eden Pharmaceuticals Farmaceutisch preparaat geschikt voor de profylaxe of therapie van een retrovirale infectie of een complicatie of gevolg daarvan.
JPS63267722A (ja) * 1987-04-27 1988-11-04 Daiichi Yakuhin Sangyo Kk 抗肥満症剤
US4835147A (en) * 1987-05-06 1989-05-30 City Of Hope Dehydroepiandrosterone therapy for ameleoration of prostate hypertrophy and sexual dysfunction
US5051260A (en) * 1987-07-16 1991-09-24 The Regents Of The University Of California Method and composition for enhancing the cutaneous penetration of pharmacologically active agents
ES2169030T3 (es) * 1987-09-24 2002-07-01 Jencap Res Ltd Envases de anticonceptivos que contienen estrogeno y progestina.
US5064654A (en) * 1989-01-11 1991-11-12 Ciba-Geigy Corporation Mixed solvent mutually enhanced transdermal therapeutic system
US5162037A (en) * 1988-04-01 1992-11-10 Whitson Laboratories, Inc. Magnetically influenced homeopathic pharmaceutical formulations, methods of their preparation and methods of their administration
US5047244A (en) * 1988-06-03 1991-09-10 Watson Laboratories, Inc. Mucoadhesive carrier for delivery of therapeutical agent
CA2004203A1 (en) * 1988-12-01 1990-06-01 Sharad K. Govil Compositions for transdermal delivery of estradiol
EP0462189B1 (de) * 1989-03-10 1995-09-27 Endorecherche Inc. Kombinationstherapie zur behandlung von estrogenempfindlichen erkrankungen
EP0595796B1 (de) * 1989-07-07 2003-01-15 Endorecherche Inc. Methode zur behandlung androgenbedingter krankheiten
US4978532A (en) * 1989-08-11 1990-12-18 Pharmedic Co. Dosage form for administration of dehydroepiandrosterone
US5116828A (en) * 1989-10-26 1992-05-26 Nippon Zoki Pharmaceutical Co., Ltd. Pharmaceutical composition for treatment of osteoporosis
GB9003939D0 (en) * 1990-02-21 1990-04-18 Imperial College Sulphatase inhibitors
US5071644A (en) * 1990-08-07 1991-12-10 Mediventures, Inc. Topical drug delivery with thermo-irreversible gels
US5162198A (en) * 1991-02-08 1992-11-10 Virginia Commonwealth University Method of using dehydroepiandrosterone and dehydroepiandrosterone-sulfate as inhibitors of thrombuxane production and platelet aggregation
US5110810A (en) * 1991-02-08 1992-05-05 Virginia Commonwealth University Method of using dehydroepiandrosterone and dehydroepiandrosterone-sulfate as inhibitors of platelet aggregation
ZA924811B (en) * 1991-06-28 1993-12-29 Endorecherche Inc Controlled release systems and low dose androgens
HU222501B1 (hu) * 1991-06-28 2003-07-28 Endorecherche Inc. MPA-t vagy MGA-t tartalmazó nyújtott hatóanyag-felszabadulású gyógyászati készítmény és eljárás előállítására

Also Published As

Publication number Publication date
JP3441730B2 (ja) 2003-09-02
JPH08505629A (ja) 1996-06-18
FI953017A0 (fi) 1995-06-19
NO321846B1 (no) 2006-07-10
NO20003546L (no) 1995-06-16
US5872114A (en) 1999-02-16
ES2261836T3 (es) 2006-11-16
NO20003549D0 (no) 2000-07-10
AU5388494A (en) 1994-07-28
US5798347A (en) 1998-08-25
HU228385B1 (en) 2013-03-28
AU686120B2 (en) 1998-02-05
PT680327E (pt) 2004-12-31
US5837700A (en) 1998-11-17
US5843932A (en) 1998-12-01
WO1994016709A2 (en) 1994-08-04
CN1439375A (zh) 2003-09-03
CZ297860B6 (cs) 2007-04-18
NO952417D0 (no) 1995-06-16
DE69433994D1 (de) 2004-10-21
AU5855794A (en) 1994-08-15
US5854229A (en) 1998-12-29
ATE275957T1 (de) 2004-10-15
EP0680327B1 (de) 2004-09-15
ATE322271T1 (de) 2006-04-15
US5948434A (en) 1999-09-07
NO314656B1 (no) 2003-04-28
EP0680327A1 (de) 1995-11-08
NO20024189D0 (no) 2002-09-03
DE69434697T2 (de) 2007-03-29
DE69433994T2 (de) 2005-09-22
NO20003545D0 (no) 2000-07-10
DK0680327T3 (da) 2005-01-03
CN1100541C (zh) 2003-02-05
CZ156595A3 (en) 1995-12-13
NO315690B1 (no) 2003-10-13
NO20003549L (no) 1995-06-16
NZ250712A (en) 1996-11-26
IL108371A0 (en) 1994-04-12
NO20003547L (no) 1995-06-16
HUT73241A (en) 1996-07-29
CN1439375B (zh) 2012-08-08
HU9501985D0 (en) 1995-09-28
NO20003547D0 (no) 2000-07-10
ES2227523T3 (es) 2005-04-01
SK286051B6 (sk) 2008-02-05
NO20003545L (no) 1995-06-16
WO1994016709A3 (en) 1994-11-24
IL108371A (en) 2009-09-01
SK77995A3 (en) 1997-04-09
NO314067B1 (no) 2003-01-27
FI953017A (fi) 1995-06-19
NO20024189L (no) 1995-06-16
NZ512334A (en) 2005-05-27
US5807849A (en) 1998-09-15
NO20003546D0 (no) 2000-07-10
CN1116823A (zh) 1996-02-14
PT1382340E (pt) 2006-07-31
NO952417L (no) 1995-06-16

Similar Documents

Publication Publication Date Title
DE69434697D1 (de) Therapeutische Verwendungen von Dehydroepiandrosteron zur Behandlung von verminderter Libido und Osteoporose
MY157883A (en) Therapeutic uses and delivery systems of dehydroepiandrosterone
AR018660A1 (es) Una composicion farmaceutica que comprende androst-5-en-3beta,17beta-diol o una prodroga del mismo; un kit y metodos terapeuticos que utilizan dicha composicion y un parche transdermico.
ATE330614T1 (de) Topisch anzuwendende östrogen/progestin enthaltende arzneimittel mit systemischer wirkung
ATE128362T1 (de) Kombinationstherapie zur behandlung von estrogenempfindlichen erkrankungen.
ATE452641T1 (de) Orale pharmazeutische zusammensetzung enthaltend 15-hydroxytestosteron und seine derivate
GB2138286A (en) Pharmaceutical composition for the treatment of hair loss
GB1274367A (en) 01beta,13beta-DIALKYLGONA-1,3,5(10)-TRIEN-3-OL 3-CYCLOALKYL ETHERS
Shouls et al. Contact allergy to testosterone in an androgen patch: control of symptoms by pre-application of topical corticosteroid.
CA2491801A1 (fr) Composes a base d'hormone donneurs de monoxyde d'azote et leur utilisation en obstetrique et en gynecologie
Nimrod et al. 88. Aromatization of androgens by human fat tissue
Ellis 90. Control of rat testicular 5α-reductase activity for testosterone and progesterone: blinding, X-irradiation, melatonin, prolactin, LH, and FSH
GB1244143A (en) Trialkyl-silyloxy-steroids
TAGA et al. Distribution and cyclic change of aromatase cytochrome P-450 activity in human uteri
Loke 89. Androsta-1, 4-diene-3, 17, 19-trione: Its provisional identification as a new placental metabolite of androstenedione
Dube et al. 91. Testosterone 5α-reductase in rat skin homogenates
Tinneberg et al. Steroide fördern Brustkrebs

Legal Events

Date Code Title Description
8364 No opposition during term of opposition